The landscape of weight-loss treatment stands at an inflection point. For the past two years, injectable glucagon-like peptide 1 receptor agonists—known colloquially as GLP-1s—have dominated conversations about obesity management and metabolic health, driven by blockbuster medications like Ozempic, Wegovy, Mounjaro, and Zepbound.
Yet 2026 will fundamentally alter the terrain through oral formulations, patent expirations, biosimilar competition, and expanded insurance access that promise to reshape everything from pharmaceutical supply chains to consumer health behaviors.
The Oral Pill Era Begins
The arrival of GLP-1 pills in 2026 represents perhaps the most significant structural shift in the drug class since its obesity indication was approved.
On December 22, 2025, the FDA granted approval to Novo Nordisk's oral semaglutide pill for weight loss, branded as Wegovy in tablet form. The company has already begun manufacturing the pill at expanded U.S. facilities and expects broad market availability to commence in early 2026.
Clinical trial data supports the oral formulation's potential. In the OASIS 4 phase 3 trial, oral semaglutide 25 mg achieved an average weight loss of 16.6% over 64 weeks in adults with obesity or overweight status combined with weight-related comorbidities.
One-third of participants lost 20% or more of their body weight, matching outcomes from injectable Wegovy trials. The safety and tolerability profile proved comparable to the injection, with nausea reported in 47% of participants versus 19% in the placebo group and discontinuation due to adverse events at 6.9% versus 5.9% in placebo recipients.
Eli Lilly's competing oral GLP-1, orforglipron, is expected to reach the market by mid-2026, pending FDA approval. The company submitted its new drug application in late 2025 for obesity treatment and planned a 2026 submission for type 2 diabetes.
Phase 3 data demonstrated that the once-daily pill produced a 22.9-pound average weight loss—roughly 8.9% of body weight—with a discontinuation rate due to gastrointestinal effects of 10.3%. These oral options eliminate the primary barrier that historically deterred patients from GLP-1 therapy: the weekly injection requirement.
Patent Cliffs and Price Pressures Unleashed
A critical inflection point arrives on March 20, 2026, when the foundational patent for semaglutide (the active ingredient in Ozempic and Wegovy) expires in multiple major markets.
Patents in Canada, Brazil, India, Turkey, and China will lapse simultaneously, opening the door for generic and biosimilar manufacturers to produce semaglutide at significantly lower costs. These regions collectively represent approximately 40% of the world's population and account for an estimated 33% of the global population with obesity.
In Canada, analysts expect semaglutide biosimilars to enter the market in the first or second quarter of 2026. Dr. Reddy's Laboratories, an Indian pharmaceutical manufacturer, has already developed a semaglutide biosimilar in global registration, with anticipated rollout in Canada, Brazil, and India.
Biocon, another Indian firm, has licensed supply agreements in Brazil with Biomm SA. Chinese manufacturers have launched at least 11 clinical trials for semaglutide generics as part of their regulatory pathways.
These off-patent entries will trigger steep price reductions. Analysts expect costs to fall by 60% to 70% in countries where patent protection expires, with some estimates suggesting manufacturing costs as low as $10 per dose.
The Brazilian market, a key bellwether, projects that the overall GLP-1 market will expand from R$6-7 billion in 2025 to approximately R$9 billion in 2026 as generic competition intensifies and access broadens.
However, the U.S. and European markets will see less disruption.
Novo Nordisk holds secondary patents covering delivery devices, formulations, and administration methods extending to approximately 2032-2033, shielding the company from generic competition in these markets despite the primary patent lapsing in 2026.
Medicare and Medicaid Reshape Access
The pricing and accessibility landscape shifted dramatically in November 2025 when the Trump administration announced two major government programs to expand GLP-1 access. Under the GENEROUS (Generating Cost Reductions for U.S.
Medicaid) model, Medicare beneficiaries will pay only $50 monthly out of pocket for qualifying GLP-1 medications. This represents a seismic change from the $900-$1,300 monthly prices uninsured patients currently face.
Under the model, Medicare will cover GLP-1 medications for beneficiaries with obesity or overweight status combined with related conditions, rolling out in phased stages beginning mid-to-late 2026. Phase 1 covers overweight individuals with BMI greater than 27 with prediabetes or cardiovascular disease.
Phase 2 extends to BMI greater than 30 with hypertension, kidney disease, or heart failure. Phase 3 includes those with BMI greater than 35. Medicaid programs will adopt an opt-in structure, allowing individual states to negotiate pricing agreements with manufacturers.
The CMS announced an additional voluntary model called BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) in December 2025, with state Medicaid agencies invited to join beginning May 2026 and Medicare Part D plans entering in January 2027.
These programs mark the federal government's first comprehensive effort to address GLP-1 affordability at scale.
Yet insurance coverage remains fragmented. Medi-Cal Rx, California's Medicaid program, removed Wegovy, Zepbound, and Saxenda from its covered drug list effective January 1, 2026, eliminating coverage for weight-loss indications even as diabetes treatment coverage continues.
This patchwork approach reflects ongoing policy tensions between expanding access and managing pharmaceutical expenditures.
Manufacturing Scrambles to Keep Pace
Behind the scenes, pharmaceutical companies and contract manufacturers are engaged in a massive capacity expansion to meet anticipated demand surges from oral formulations and expanded insurance coverage.
Eli Lilly has invested more than $18 billion since 2020 in facility construction, expansion, and acquisition, with a $4.5 billion advanced manufacturing facility in Indiana and a new $1.2 billion facility in Puerto Rico. The company acquired an injectable manufacturing facility in Wisconsin slated to begin production in 2026.
Novo Nordisk executed a $16.5 billion acquisition of Catalent, a contract development and manufacturing organization, to accelerate GLP-1 production capacity. CordenPharma, another major contract manufacturer, pledged €900 million ($981 million) over three years to expand GLP-1 peptide manufacturing in Europe and the United States.
Simtra BioPharma is constructing a 150,000-square-foot facility in Bloomington, Indiana dedicated to fill-and-finish operations for GLP-1 drugs, with production expected to commence in 2026.
Despite these investments, supply constraints are projected to persist through 2026. European regulators flagged GLP-1 shortages as a serious public health concern, warning that widespread availability will likely remain limited even after manufacturing capacity expansions complete.
This chronic undersupply has paradoxically strengthened the market for compounded GLP-1 medications sourced from telehealth platforms and specialized pharmacies.
Compounded Drugs Retain Market Share Despite Regulatory Scrutiny
While shortages have largely resolved at brand-name manufacturers, compounded GLP-1s—created by licensed pharmacies using the same active ingredients but without FDA oversight—remain ubiquitous and expanding.
From late 2022 through early 2025, compounding pharmacies filled a critical supply gap during widespread brand-name shortages, enabling telehealth platforms like Hims and Ro to offer lower-cost alternatives. Even as manufacturing improved and FDA shortage designations were lifted, compounded prescriptions continued rising.
Over 80% of compounded semaglutide and tirzepatide prescriptions now include supplemental ingredients such as B vitamins, B12, or levocarnitine, positioned to consumers as metabolism-enhancing additions.
These formulations lack FDA approval as finished products and have not undergone FDA safety and efficacy evaluation. The FDA has warned about potential dosing errors and undisclosed additives that can alter a drug's pharmacokinetics and safety profile.
Brand-name manufacturers Novo Nordisk and Eli Lilly, recognizing compounded competition, initiated discount programs in 2025 for uninsured patients purchasing directly without insurance.
Novo offers Wegovy through NovoCare Pharmacy at approximately $499 monthly, matching Eli Lilly's cash-pay pricing strategy. These discounts reflect competitive pressure rather than philanthropic motives—companies needed to defend market share against lower-priced compounded alternatives.
Emerging Competition from Next-Generation Therapies
While Novo Nordisk and Eli Lilly dominate the GLP-1 space, competition is intensifying from dual and triple agonist therapies that target multiple appetite-regulating hormonal pathways simultaneously. Amgen's MariTide, a monoclonal antibody conjugate designed to activate GLP-1 receptors while inhibiting GIP receptors, entered phase 3 trials in March 2025.
Phase 2 data demonstrated up to 20% weight loss over 52 weeks with monthly dosing—a significant advantage over weekly injections. Amgen expects phase 3 results in early 2027, pushing approval into 2027 or 2028 at the earliest.
Viking Therapeutics' VK2735, a dual GLP-1/GIP agonist available in both subcutaneous and oral formulations, initiated phase 3 trials (VANQUISH-1 and VANQUISH-2) in June 2025 with enrollment completion in November 2025.
Phase 2 data showed up to 14.7% weight loss over 13 weeks with a favorable safety and tolerability profile. Results from the VENTURE-Oral Dosing trial demonstrated that the once-daily oral formulation achieved up to 12% weight loss.
Eli Lilly's retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, represents the most aggressive molecular strategy. Phase 2 data revealed that the highest dose produced 24.2% weight loss over 48 weeks—exceeding results from current GLP-1 monotherapies and dual agonists.
However, the FDA approval timeline extends well beyond 2026, with the company conducting extensive phase 3 trials expected to conclude in 2025-2026 for diabetes and later for obesity.
New Indications Expanding Beyond Obesity
The clinical application of GLP-1s is broadening rapidly beyond their original use in diabetes and approved weight-loss indications. Cardiovascular benefits are now well established: meta-analysis of major clinical trials demonstrated that GLP-1 receptor agonists reduce major adverse cardiovascular events by 13%, cardiovascular death by 14%, and all-cause mortality by 13% in type 2 diabetes patients.
These benefits extend to patients regardless of initial weight loss magnitude, suggesting pleiotropic mechanisms beyond weight reduction.
The World Health Organization issued global guidelines on GLP-1 use in obesity treatment in December 2025, acknowledging cardiovascular protection as a key clinical benefit.
Research programs are now investigating GLP-1s for Alzheimer's disease, polycystic ovary syndrome (PCOS), nonalcoholic fatty liver disease (NAFLD), heart failure, and peripheral arterial disease.
Insurance formularies and clinical guidelines increasingly recognize GLP-1s as appropriate treatment for cardiovascular disease patients without diabetes, a significant expansion of the addressable patient population.
This reframing from obesity drugs to cardiometabolic therapeutics may accelerate adoption among healthcare providers and payers seeking multifaceted risk reduction.
Consumer Behavior and Market Disruption
The penetration of GLP-1s into American households has reached critical mass. Market research indicates that approximately 25% of U.S.
households have used GLP-1 medications on a temporary or cyclical basis, with 35% expressing interest in trying them. Most users engage with a GLP-1 for six to twelve months, with cost cited as the primary reason for discontinuation.
This medication-driven consumer behavior is reshaping food and retail markets. According to Circana research, GLP-1 users purchase fewer food and beverage items, with spending shifting toward oral care and self-care products.
Consumption patterns are shifting toward protein-rich meals and fresh or refrigerated options over packaged foods, while alcohol consumption declines among users. If current adoption trends persist, Circana projects that by 2030, GLP-1 users will influence 35% of food and beverage purchasing decisions and 37% of non-food purchases in U.S. households.
Major retailers including Albertsons, Kroger, and Sprouts Farmers Market, alongside protein producers like Hormel Foods, Smithfield Foods, and Tyson Foods, are positioned to benefit from these shifts.
Consumer staples companies are responding with product innovations; PepsiCo announced functional beverages including Muscle Milk with no artificial sweeteners, Starbucks Coffee & Protein, and Propel Protein Water to capture GLP-1 user preferences.
Market Size and Forecast Trajectories
The global GLP-1 market is on a steep growth trajectory. The market size is projected at $58-101 billion in 2026, with compound annual growth rates ranging from 8.7% to 13% through 2035.
By 2035, the market is expected to reach $132-180 billion. North America represents the dominant regional market, accounting for 64% of global GLP-1 sales.
Within the market, tirzepatide products (Mounjaro and Zepbound) are showing the fastest growth rates, capturing market share from semaglutide-based drugs.
Tirzepatide's dual GLP-1/GIP mechanism and demonstrated clinical efficacy are driving adoption. In Q3 2025, Eli Lilly's tirzepatide franchise generated $10.1 billion in quarterly revenue alone.
The injectable segment dominated the market in 2024 with 83% share, but oral formulations are expected to capture increasing market share as they achieve regulatory approval and market launch.
Oral accessibility may accelerate adoption among patient populations previously deterred by injection anxiety—a significant untapped market given that fewer than 2% of Americans with obesity currently receive pharmaceutical treatment.
2026: Year of Transition and Transformation
The convergence of oral pill approvals, patent expirations, government insurance programs, and next-generation competing therapies will fundamentally transform the GLP-1 market in 2026.
The transition from weekly injections to daily pills reduces a major barrier to treatment adoption, potentially expanding the patient population from its current 8% to substantially higher penetration rates. Patent expirations in major emerging markets will democratize access to lower-income populations historically priced out of obesity treatment.
Government insurance expansions through Medicare and Medicaid will remove financial barriers for millions of beneficiaries, though implementation challenges and state-by-state variation in Medicaid programs will create pockets of access and gaps.
Manufacturing capacity expansions, while substantial, may struggle to keep pace with demand surges from these access-expanding initiatives.
Competitive dynamics will intensify as oral formulations enter the market and next-generation therapies progress toward approval. The era of GLP-1 market dominance by injectable semaglutide and tirzepatide is ending.
The era of choice—among formulations, mechanisms, dosing schedules, and price points—is beginning. For patients, payers, and healthcare providers, 2026 will be the year when a niche blockbuster drug class transforms into a mainstream standard of care for obesity, diabetes, and cardiovascular disease management.
